Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation

(2011) W. J. Norde et al.   CANCER RESEARCH

HIV controllers: A multifactorial phenotype of spontaneous viral suppression

(2011) Jacques Thèze et al.   CLINICAL IMMUNOLOGY

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells

(2011) Genc Basha et al.   MOLECULAR THERAPY

Therapeutic siRNA silencing in inflammatory monocytes in mice

(2011) Florian Leuschner et al.   NATURE BIOTECHNOLOGY

Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection

(2011) Felipe García et al.   VACCINE

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells

(2010) W. Hobo et al.   BLOOD

mRNA as gene therapeutic: How to control protein expression

(2010) Geertrui Tavernier et al.   JOURNAL OF CONTROLLED RELEASE

Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

(2010) Akin Akinc et al.   MOLECULAR THERAPY

Rational design of cationic lipids for siRNA delivery

(2010) Sean C Semple et al.   NATURE BIOTECHNOLOGY

Lipid-like materials for low-dose, in vivo gene silencing

(2010) K. T. Love et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Dendritic cell-based therapeutic cancer vaccines: what we have and what we need

(2009) Pawel Kalinski et al.   Future Oncology

siRNA Knockdown of PD-L1 and PD-L2 in Monocyte-Derived Dendritic Cells only Modestly Improves Proliferative Responses to Gag by CD8+ T Cells from HIV-1-Infected Individuals

(2009) Gaëlle Breton et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Efficient Activation of LRH-1–specific CD8+ T-cell Responses From Transplanted Leukemia Patients by Stimulation With P2X5 mRNA-electroporated Dendritic Cells

(2009) Ingrid M. Overes et al.   JOURNAL OF IMMUNOTHERAPY

A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery

(2009) James J. Lu et al.   MOLECULAR PHARMACEUTICS

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

(2008) Lotte Engell-Noerregaard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Studies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic Potential

(2008) Özcan Met et al.   MOLECULAR BIOTECHNOLOGY

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

(2008) Akin Akinc et al.   NATURE BIOTECHNOLOGY

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA